Cardinal Health (CAH)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$247.18-0.58%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
QuarterlyIQ Insights · CAH
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 0% of the last 1 guided quarters · -74.7% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Deliver non-GAAP diluted EPS growth of 13% to 15% in fiscal 2027, with segment profit growth and operational execution driving results.
Stated as a priority in 4 of last 4 quarters. Non-GAAP diluted EPS guidance increased from $9.65-$9.85 in 2026-Q1 to $12.40-$12.60 for fiscal 2027 in 2026-Q4, reflecting management's consistent emphasis on EPS growth. The trajectory is delivering with raised guidance and strong segment profit growth.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Cardinal Health provides fiscal year 2027 non-GAAP EPS guidance of +13% to +15% growth ($12.40 to $12.60).”
“Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance to $10.70 to $10.80 (+30% to +31% growth).”
“Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance to $10.15 to $10.35 (+23% to +26% growth).”
“Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance to $9.65 to $9.85 (+17% to +20% growth).”
Grow Pharmaceutical and Specialty Solutions segment profit by double digits through brand, specialty products, and acquisitions.
Stated as a priority in 4 of last 4 quarters. Pharmaceutical and Specialty Solutions segment profit increased from $535 million in 2025-Q4 to $645 million in 2026-Q4 (+21% year-over-year), reflecting management's focus on brand, specialty products, and acquisitions. The trajectory is delivering consistent double-digit profit growth.
“Pharmaceutical and Specialty Solutions segment profit increased 21% to $645 million in Q4 FY26.”
“Pharmaceutical and Specialty Solutions segment profit increased 18% to $784 million in Q3 FY26.”
“Pharmaceutical and Specialty Solutions segment profit increased 29% to $687 million in Q2 FY26.”
“Pharmaceutical and Specialty Solutions segment profit increased 26% to $667 million in Q1 FY26.”
Generate adjusted free cash flow in the range of $3.5 billion to $4.0 billion for fiscal 2027.
Stated as a priority in 4 of last 4 quarters. Adjusted free cash flow guidance increased from $3.0-$3.5 billion in 2026-Q1 to $3.5-$4.0 billion for fiscal 2027 in 2026-Q4, showing management's focus on cash generation. The trajectory is delivering with raised and narrowed guidance.
“Non-GAAP adjusted free cash flow guidance for fiscal 2027 is $3.5 billion to $4.0 billion.”
“Adjusted free cash flow raised and narrowed to $3.3 billion to $3.7 billion for fiscal 2026.”
“Adjusted free cash flow raised to $3.0 billion to $3.5 billion for fiscal 2026.”
“Adjusted free cash flow raised to $3.0 billion to $3.5 billion for fiscal 2026.”
Continue share repurchases with a target of approximately $1 billion in fiscal year 2027, supported by board authorization.
Stated as a priority in 3 of last 4 quarters. Share repurchases totaled $1.4 billion in fiscal 2026, including accelerated programs, with a target of approximately $1 billion for fiscal 2027 and a $5.0 billion increase in authorization approved by the board. The trajectory shows active execution and continued commitment.
“Cardinal Health plans share repurchases of ~$1 billion in fiscal year 2027; Board approved $5.0 billion increase to share repurchase authorization.”
“Cardinal Health completed additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billion.”
“Cardinal Health completes annual baseline share repurchase of $750 million.”
Complete accelerated share repurchase programs and maintain disciplined capital allocation with targeted $750 million repurchases in fiscal 2026.
Over the trailing year it converted 0.90x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.